Novaliq GmbH, a Heidelberg, Germany-based drug delivery company, completed a €13.9m ($18.1m) fifth round of financing.
The backer was Dievini Hopp Bio Tech Holding GmbH & Co. KG.
The company intends to use the funds to progress its pharmaceutical project CyclASol™ into clinical development, and extend its technology platform.
Led by Bernhard Günther, CEO, Novaliq develops a superior generation of ocular formulations for poorly soluble drugs. Its patented ocular formulations are based on semifluorinated alkanes (SFAs), which can be applied in the form of topical eye drops.
FinSMEs
11/04/2013